| Literature DB >> 25483525 |
R Mark Jones1, Jessica A Chichester, Slobodanka Manceva, Sandra K Gibbs, Konstantin Musiychuk, Moneim Shamloul, Joey Norikane, Stephen J Streatfield, Marga van de Vegte-Bolmer, Will Roeffen, Robert W Sauerwein, Vidadi Yusibov.
Abstract
Malaria transmission blocking vaccines (TBV) directed against proteins expressed on sexual stages of Plasmodium falciparum in the mosquito midgut are considered an effective means to reduce malaria transmission. Antibodies induced by TBV block sporogonic development in the mosquito, and thus transmission to the next human host. The Pfs25 protein, expressed on the surface of gametes, zygotes and ookinetes, is one of the primary targets for TBV development. Using a plant virus-based transient expression system, we have successfully produced Pfs25 fused to a modified lichenase (LicKM) carrier in Nicotiana benthamiana, purified and characterized the protein (Pfs25-FhCMB), and evaluated this vaccine candidate in animal models for the induction of transmission blocking antibodies. Soluble Pfs25-FhCMB was expressed in plants at a high level, and induced transmission blocking antibodies that persisted for up to 6 months post immunization in mice and rabbits. These data demonstrate the potential of the new malaria vaccine candidate and also support feasibility of expressing Plasmodium antigens in a plant-based system.Entities:
Keywords: Pfs25; Plasmodium falciparum; fusion protein; lichenase; malaria; plant-produced antigen; subunit vaccine; transmission blocking vaccine
Mesh：
Substances：
Year: 2014 PMID： 25483525 PMCID： PMC4514342 DOI： 10.4161/hv.34366
Source DB: PubMed Journal: Hum Vaccin Immunother ISSN： 2164-5515 Impact factor: 3.452